5 Things You Need to Know About Statin Selection in Patients With HIV Infection
Overview
Increase in Proportionate CVD Mortality Rates in the HIV-Infected Population Since 1999, While Declining in Others
Why Has CVD Mortality Increased Among HIV-Infected Persons?
Assessment of CVD Risk in Patients With HIV Infection
Viral and ART Factors Contribute to Increased VLDL and Decreased HDL Levels
Importance of Statins in Patients With HIV Infection: Beyond LDL-C Reduction?
Role for Statins in Patients With HIV Infection
Mean Changes in Blood Lipids for 50 Seroconverters Initiating HAART
Contemporary ART: More Lipid Neutral
Assessment of CV Risk in the HIV-Infected Patient
Atorvastatin Effects on ASCVD Progression in HIV Infection Reduced Plaque Progression vs Placebo
Rosuvastatin Effects on CCA-IMT in HIV Infection: Reduced Carotid IMT Progression vs Placebo -- SATURN Trial
Use of Statins With Protease Inhibitors
Lifestyle and Pharmacologic Modification of Nonlipid CVD Risk Factors
REPRIEVE Trial Design
REPRIEVE Trial Hypotheses
Why Pitavastatin in REPRIEVE?
Concluding Remarks
Abbreviations
Abbreviations (cont)